A pharmaceutical composition comprising hydroxychloroquine, chloroquine, or metabolite thereof
A pharmaceutical composition consisting of: a first pharmaceutically active portion consisting of hydroxychloroquine or a salt thereof and/or chloroquine or a salt thereof; a second pharmaceutically active portion consisting of one or more of glutathione, cysteine, acetylcysteine, alliin, bucillamine, carbocysteine, djenkolic acid, felinine, lanthionine, mecysteine hydrochloride, penicillamine cysteine disulphide, or any functional equivalent thereof; and optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active portion to the first pharmaceutically active portion is at least 0.5:1 is provided. The second active portion preferably consists of glutathione. The pharmaceutical composition for use in the treatment of malaria, lupus, rheumatoid arthritis, or severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is provided. A pharmaceutical composition consisting of a first pharmaceutically active portion consisting of N-desethylhydroxychloroquine and/or N-desethylchloroquine or a salt thereof; and optionally one or more excipients is disclosed..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 17. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
PETER WHITTON [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-11-17, Last update posted on www.tib.eu: 2022-09-04, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
GB2594918 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013409190 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013409190 | ||
| 003 | DE-627 | ||
| 005 | 20230503182133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013409190 | ||
| 035 | |a (EPA)GB2594918 | ||
| 035 | |a (EPA)70553569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a PETER WHITTON |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A pharmaceutical composition comprising hydroxychloroquine, chloroquine, or metabolite thereof |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-11-17, Last update posted on www.tib.eu: 2022-09-04, Last updated: 2023-02-09 | ||
| 520 | |a A pharmaceutical composition consisting of: a first pharmaceutically active portion consisting of hydroxychloroquine or a salt thereof and/or chloroquine or a salt thereof; a second pharmaceutically active portion consisting of one or more of glutathione, cysteine, acetylcysteine, alliin, bucillamine, carbocysteine, djenkolic acid, felinine, lanthionine, mecysteine hydrochloride, penicillamine cysteine disulphide, or any functional equivalent thereof; and optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active portion to the first pharmaceutically active portion is at least 0.5:1 is provided. The second active portion preferably consists of glutathione. The pharmaceutical composition for use in the treatment of malaria, lupus, rheumatoid arthritis, or severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is provided. A pharmaceutical composition consisting of a first pharmaceutically active portion consisting of N-desethylhydroxychloroquine and/or N-desethylchloroquine or a salt thereof; and optionally one or more excipients is disclosed. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 17. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:17 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/70553569/publication/GB2594918A1?q=GB2594918 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 17 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 17 |c 11 | ||